Lamisil 250 mg tablete
Name | Lamisil 250 mg tablete |
---|---|
Marketing Authorisation Number | HR-H-798097379 |
Active Substance | terbinafinklorid |
Composition | jedna tableta sadrži 250 mg terbinafina (u obliku terbinafinklorida) |
Pharmaceutical Form | tableta |
Manufacturer | Novartis Pharma GmbH, Nürnberg, Njemačka Lek Pharmaceuticals d.d., Lendava, Slovenija Novartis Farmacéutica S.A., Barcelona, Španjolska |
Marketing Authorisation Holder | Novartis Hrvatska d.o.o., Radnička cesta 37b, Zagreb, Hrvatska |
Marketing Authorisation Date | 04.09.2018 |
MA Period of Validity | unlimited |
Classification Number | UP/I-530-09/17-02/389 |
Registration Number | 381-12-01/38-18-06 |
Prescription | na recept |
Type of prescription | neponovljivi recept |
Distribution | u ljekarni |
Advertising to general public | zabranjeno |
ATC Code | D01BA02 |
Medicinal product marketed in the Croatia | Da |
SmPC | download |
PL | download |